Allianz Asset Management
CHRS icon

Allianz Asset Management’s Coherus Oncology CHRS Stock Holding History

Allianz Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-216,600
Closed -$925K – 2192
2023
Q2 		$925K Buy
+216,600
New +$1.28M ﹤0.01% 1557
2021
Q2 		– Sell
-170,168
Closed -$2.49M – 2401
2021
Q1 		$2.49M Buy
170,168
+64,453
+61% +$1.09M ﹤0.01% 1326
2020
Q4 		$1.84M Hold
105,715
– – ﹤0.01% 1340
2020
Q3 		$1.94M Sell
105,715
-14,424
-12% -$268K ﹤0.01% 1274
2020
Q2 		$2.15M Buy
120,139
+100,479
+511% +$1.7M ﹤0.01% 1576
2020
Q1 		$318K Sell
19,660
-9,453
-32% -$175K ﹤0.01% 2207
2019
Q4 		$525K Sell
29,113
-137
-0.5% -$2.53K ﹤0.01% 2419
2019
Q3 		$592K Buy
+29,250
New +$584K ﹤0.01% 2313
2017
Q2 		– Sell
-189,745
Closed -$3.98M – 2613
2017
Q1 		$3.98M Buy
189,745
+27,140
+17% +$668K ﹤0.01% 1721
2016
Q4 		$4.58M Buy
162,605
+20,300
+14% +$568K ﹤0.01% 1681
2016
Q3 		$3.74M Buy
142,305
+96,046
+208% +$2.62M ﹤0.01% 1736
2016
Q2 		$781K Buy
+46,259
New +$868K ﹤0.01% 2224

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Allianz Asset Management's CHRS Position: Q3 2023 in Review

Allianz Asset Management sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 216,600 shares — an estimated $925K sold.

Allianz Asset Management first reported a position in CHRS in Q2 2016 and held it in 12 quarters. The position peaked at $4.58M in Q4 2016. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

  • Allianz Asset Management reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
  • Allianz Asset Management sold 216,600 Coherus Oncology shares in Q3 2023, an estimated $925K.
  • Allianz Asset Management first reported a position in Coherus Oncology in Q2 2016 and held it in 12 quarters.
  • Allianz Asset Management's Coherus Oncology position peaked at $4.58M in Q4 2016.
  • 169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Allianz Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.